SG11202103033WA - Compositions and methods for the treatment of presbyopia - Google Patents
Compositions and methods for the treatment of presbyopiaInfo
- Publication number
- SG11202103033WA SG11202103033WA SG11202103033WA SG11202103033WA SG11202103033WA SG 11202103033W A SG11202103033W A SG 11202103033WA SG 11202103033W A SG11202103033W A SG 11202103033WA SG 11202103033W A SG11202103033W A SG 11202103033WA SG 11202103033W A SG11202103033W A SG 11202103033WA
- Authority
- SG
- Singapore
- Prior art keywords
- presbyopia
- compositions
- treatment
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/1412—Containers with closing means, e.g. caps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862743720P | 2018-10-10 | 2018-10-10 | |
| PCT/US2019/055116 WO2020076769A1 (en) | 2018-10-10 | 2019-10-08 | Compositions and methods for the treatment of presbyopia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202103033WA true SG11202103033WA (en) | 2021-04-29 |
Family
ID=70161531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202103033WA SG11202103033WA (en) | 2018-10-10 | 2019-10-08 | Compositions and methods for the treatment of presbyopia |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10836760B2 (pt) |
| EP (1) | EP3863630A4 (pt) |
| JP (1) | JP2022504746A (pt) |
| KR (1) | KR20210076941A (pt) |
| CN (1) | CN113518620A (pt) |
| AU (1) | AU2019357979A1 (pt) |
| BR (1) | BR112021006618B1 (pt) |
| CA (1) | CA3114204A1 (pt) |
| MA (1) | MA53873A (pt) |
| MX (1) | MX2021004183A (pt) |
| SG (1) | SG11202103033WA (pt) |
| WO (1) | WO2020076769A1 (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210251970A1 (en) | 2018-10-10 | 2021-08-19 | Presbyopia Therapies Inc | Compositions and methods for storage stable ophthalmic drugs |
| WO2021222525A1 (en) * | 2020-04-30 | 2021-11-04 | Eye Therapies, Llc | Brimonidine compositions and methods of use |
| CA3195422A1 (en) * | 2020-10-13 | 2022-04-21 | Gerald Horn | Compositions and methods for storage stable ophthalmic drugs |
| US20220347170A1 (en) * | 2021-04-28 | 2022-11-03 | Lenz Therapeutics, Inc. | Method of Reducing Brow Ache |
| CN116459251A (zh) * | 2022-01-18 | 2023-07-21 | 苏州普乐康医药科技有限公司 | 一种含西维美林的眼用制剂及其制备方法和应用 |
| TW202329958A (zh) * | 2022-01-25 | 2023-08-01 | 張金明 | 西維美林水溶液組合物和使用方法 |
| US20230310380A1 (en) * | 2022-04-05 | 2023-10-05 | Alan Neil Glazier | Methods, devices, and systems for treating lens protein aggregation diseases |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0632649B2 (ja) * | 1986-02-20 | 1994-05-02 | ロ−ト製薬株式会社 | 液状医薬品包装体 |
| AU4653993A (en) * | 1992-07-02 | 1994-01-31 | Telor Ophthalmic Pharmaceuticals, Inc. | Methods and products for treating presbyopia |
| JP3849736B2 (ja) * | 1998-04-13 | 2006-11-22 | ライオン株式会社 | 易酸化物質又はこれを含む組成物の包装体及び易酸化物質の安定化方法 |
| US20090297566A1 (en) * | 2004-12-27 | 2009-12-03 | Brinkman Kyle R | Oxygen-impervious packaging with optional oxygen scavenger, stabilized thyroid hormone compositions and methods for storing thyroid hormone pharmaceutical compositions |
| US10307408B2 (en) * | 2013-08-28 | 2019-06-04 | Presbyopia Therapies, LLC | Contact lens compositions and methods for the treatment of presbyopia |
| US20190038609A1 (en) * | 2013-08-28 | 2019-02-07 | Presbyopia Therapies, LLC | Compositions and methods for the treatment of presbyopia |
| US9320709B2 (en) * | 2013-08-28 | 2016-04-26 | Presbyopia Therapies Llc | Storage stable compositions and methods for the treatment of refractive errors of the eye |
| CA2987787C (en) * | 2015-06-18 | 2023-06-27 | Presbyopia Therapies, LLC | Compositions for the improvement of distance vision and the treatment of refractive errors of the eye |
| ES2904580T3 (es) * | 2015-09-24 | 2022-04-05 | Novartis Ag | Composiciones de éster de colina del ácido lipoico y métodos para generar formulaciones oftálmicas biocompatibles. |
| KR102487614B1 (ko) * | 2015-10-06 | 2023-01-12 | 에이치엘비테라퓨틱스 주식회사 | 티모신 β4를 포함하는 안약의 제조방법 |
| WO2017160548A1 (en) * | 2016-03-17 | 2017-09-21 | Presbyopia Therapies, LLC | Compositions and methods for the treatment of presbyopia |
-
2019
- 2019-10-08 MX MX2021004183A patent/MX2021004183A/es unknown
- 2019-10-08 US US16/595,789 patent/US10836760B2/en active Active
- 2019-10-08 BR BR112021006618-7A patent/BR112021006618B1/pt active IP Right Grant
- 2019-10-08 JP JP2021519886A patent/JP2022504746A/ja active Pending
- 2019-10-08 MA MA053873A patent/MA53873A/fr unknown
- 2019-10-08 CA CA3114204A patent/CA3114204A1/en active Pending
- 2019-10-08 EP EP19871827.2A patent/EP3863630A4/en active Pending
- 2019-10-08 CN CN201980067359.1A patent/CN113518620A/zh active Pending
- 2019-10-08 KR KR1020217014044A patent/KR20210076941A/ko unknown
- 2019-10-08 SG SG11202103033WA patent/SG11202103033WA/en unknown
- 2019-10-08 WO PCT/US2019/055116 patent/WO2020076769A1/en active Application Filing
- 2019-10-08 AU AU2019357979A patent/AU2019357979A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210076941A (ko) | 2021-06-24 |
| US20200115377A1 (en) | 2020-04-16 |
| JP2022504746A (ja) | 2022-01-13 |
| EP3863630A1 (en) | 2021-08-18 |
| EP3863630A4 (en) | 2022-06-29 |
| MX2021004183A (es) | 2021-10-26 |
| US10836760B2 (en) | 2020-11-17 |
| WO2020076769A1 (en) | 2020-04-16 |
| BR112021006618B1 (pt) | 2022-09-27 |
| MA53873A (fr) | 2022-01-19 |
| BR112021006618A2 (pt) | 2021-07-06 |
| CA3114204A1 (en) | 2020-04-16 |
| AU2019357979A1 (en) | 2021-04-29 |
| CN113518620A (zh) | 2021-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL268406A (en) | Preparations and methods for treating hemoglobin diseases | |
| EP3675882A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS | |
| SG11202103033WA (en) | Compositions and methods for the treatment of presbyopia | |
| IL275626A (en) | Preparations and methods for surface treatment | |
| ZA202002066B (en) | Compositions and methods for the treatment of eye disorders | |
| IL275182A (en) | Preparations and methods for the treatment of metabolic conditions | |
| IL272121A (en) | Preparation and methods for the treatment of myopia | |
| EP3429584A4 (en) | COMPOSITIONS AND METHODS FOR TREATING PRESBYOPIA | |
| IL287796A (en) | Preparations and methods for the treatment of diseases mediated by ATPase | |
| ZA202101362B (en) | Compositions and methods for treating the eye | |
| EP3833340A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYTIA | |
| IL272937A (en) | Preparations and methods for the treatment of diseases involving fibrosis | |
| IL263477A (en) | Compositions and methods for the treatment or prevention of oxalate-related disorders | |
| IL262508A (en) | Methods and preparations for the treatment of degenerate bone | |
| ZA202101342B (en) | Compositions and methods for treating the eye | |
| IL280348A (en) | Preparations and methods for surface treatment | |
| EP3368048A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOID DOSE | |
| SG11202104053TA (en) | Compositions and methods for the treatment of estrogen-dependent disorders | |
| IL278978A (en) | Preparations and methods for treating eczema | |
| SG11201809811VA (en) | Compositions and methods for treatment of inflammation or infection of the eye | |
| IL264977A (en) | Methods and preparations for the treatment of melanoma | |
| ZA202101361B (en) | Compositions and methods for treating the eye | |
| ZA202101360B (en) | Compositions and methods for treating the eye | |
| IL272147A (en) | Methods and preparations for the treatment of cancer | |
| GB201810923D0 (en) | Compositions and method of treatment |